Cancer immunotherapy – revisited (Q37908998)

25 August 2017

1 reference

title

Cancer immunotherapy--revisited (English)

1 reference

25 August 2017

Cancer immunotherapy – revisited (English)

1 reference

8 December 2024

1 reference

2

John B A G Haanen

1 reference

25 August 2017

1

W. Joost Lesterhuis

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21804596

8 December 2024

author name string

Cornelis J. A. Punt

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21804596

8 December 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21804596

8 December 2024

publication date

1 August 2011

1 reference

full work available at URL

25 August 2017

http://www.nature.com/articles/nrd3500.pdf

file format

Portable Document Format

1 reference

http://www.nature.com/articles/nrd3500

8 December 2024

1 reference

Nature Reviews Drug Discovery

8 December 2024

published in

1 reference

25 August 2017

volume

10

1 reference

25 August 2017

issue

8

1 reference

25 August 2017

page(s)

591-600

1 reference

Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy

25 August 2017

cites work

1 reference

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

21 January 2018

1 reference

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

21 January 2018

1 reference

Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia

21 January 2018

1 reference

Why do viruses cause cancer? Highlights of the first century of human tumour virology

21 January 2018

1 reference

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma

21 January 2018

1 reference

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

Immune therapy for cancer

21 January 2018

1 reference

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial

21 January 2018

1 reference

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

21 January 2018

1 reference

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

21 January 2018

1 reference

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

21 January 2018

1 reference

Phase I/II study of ipilimumab for patients with metastatic melanoma

21 January 2018

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

Inhibitory B7-family molecules in the tumour microenvironment

21 January 2018

1 reference

Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

21 January 2018

1 reference

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

21 January 2018

1 reference

Tumor-Infiltrating FOXP3 T Regulatory Cells Show Strong Prognostic Significance in Colorectal Cancer

21 January 2018

1 reference

The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation

21 January 2018

1 reference

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

21 January 2018

1 reference

Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells

21 January 2018

1 reference

IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity

21 January 2018

1 reference

Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and [...]

21 January 2018

1 reference

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients

21 January 2018

1 reference

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

21 January 2018

1 reference

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

21 January 2018

1 reference

Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients

21 January 2018

1 reference

Cancer regression in patients after transfer of genetically engineered lymphocytes

21 January 2018

1 reference

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

21 January 2018

1 reference

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

21 January 2018

1 reference

Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo

21 January 2018

1 reference

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

21 January 2018

1 reference

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

21 January 2018

1 reference

Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells.

21 January 2018

1 reference

"MIATA"-minimal information about T cell assays

21 January 2018

1 reference

Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen

21 January 2018

1 reference

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

Ipilimumab: controversies in its development, utility and autoimmune adverse events

21 January 2018

1 reference

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

Improved Endpoints for Cancer Immunotherapy Trials

21 January 2018

1 reference

The anticancer immune response: indispensable for therapeutic success?

21 January 2018

1 reference

Inhibition of CD4( )25 T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide

21 January 2018

1 reference

Calreticulin exposure dictates the immunogenicity of cancer cell death

21 January 2018

1 reference

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

21 January 2018

1 reference

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors

21 January 2018

1 reference

Immunogenic death of colon cancer cells treated with oxaliplatin

21 January 2018

1 reference

Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients.

21 January 2018

1 reference

A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients.

21 January 2018

1 reference

In vivo colocalization of antigen and CpG [corrected] within dendritic cells is associated with the efficacy of cancer immunotherapy

21 January 2018

1 reference

CD4 T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation

21 January 2018

1 reference

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

CpG oligodeoxynucleotide enhances tumor response to radiation

21 January 2018

1 reference

Immunotherapy of distant metastatic disease.

21 January 2018

1 reference

Designing Vaccines Based on Biology of Human Dendritic Cell Subsets

21 January 2018

1 reference

Dendritic cell vaccines in melanoma: from promise to proof?

21 January 2018

1 reference

Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy

21 January 2018

1 reference

Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.

21 January 2018

1 reference

Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism

21 January 2018

1 reference

Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes

21 January 2018

1 reference

Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells

21 January 2018

1 reference

Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia

21 January 2018

1 reference

Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration

21 January 2018

1 reference

5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity

21 January 2018

1 reference

Selective depletion of CD4 CD25 Foxp3 regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels

21 January 2018

1 reference

Reduced frequencies and suppressive function of CD4 CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine

21 January 2018

1 reference

Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients.

21 January 2018

1 reference

Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A(*)02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro

21 January 2018

1 reference

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice

21 January 2018

1 reference

Cancer; a biological approach. I. The processes of control

21 January 2018

1 reference

Immunological surveillance against altered self components by sensitised T lymphocytes in lymphocytes choriomeningitis

21 January 2018

1 reference

Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system.

21 January 2018

1 reference

Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution

21 January 2018

1 reference

Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay

21 January 2018

1 reference

The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults

21 January 2018

1 reference

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

21 January 2018

1 reference

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor

21 January 2018

1 reference

A human homologue of the Drosophila Toll protein signals activation of adaptive immunity

21 January 2018

1 reference

A Toll-like receptor recognizes bacterial DNA

21 January 2018

1 reference

Clearance rates and systemic effects of intravenously administered interleukin 2 (IL-2) containing preparations in human subjects

21 January 2018

1 reference

Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers

21 January 2018

1 reference

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

21 January 2018

1 reference

Treatment of vulvar intraepithelial neoplasia with topical imiquimod

21 January 2018

1 reference

Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy

21 January 2018

1 reference

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

In situ tumor ablation creates an antigen source for the generation of antitumor immunity

21 January 2018

1 reference

The biological treatment of renal-cell carcinoma and melanoma

21 January 2018

1 reference

Quantification of Regulatory T Cells Enables the Identification of High-Risk Breast Cancer Patients and Those at Risk of Late Relapse

21 January 2018

1 reference

Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients

21 January 2018

1 reference

Immunomonitoring Tumor-Specific T Cells in Delayed-Type Hypersensitivity Skin Biopsies After Dendritic Cell Vaccination Correlates With Clinical Outcome

21 January 2018

1 reference

Toll-dependent selection of microbial antigens for presentation by dendritic cells

21 January 2018

1 reference

Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma

21 January 2018

1 reference

Landmark approval for Dendreon's cancer vaccine

31 March 2020

1 reference

Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma

31 March 2020

1 reference

Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy

31 March 2020

1 reference

Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma

31 March 2020

1 reference

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

31 March 2020

1 reference

Frequency of Circulating Tregs with Demethylated FOXP3 Intron 1 in Melanoma Patients Receiving Tumor Vaccines and Potentially Treg-Depleting Agents

31 March 2020

1 reference

Regression of Established Tumors and Induction of Tumor Immunity by Intratumor Chemotherapy

31 March 2020

1 reference

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

31 March 2020

1 reference

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

31 March 2020

1 reference

Lymphopenia and interleukin-2 therapy alter homeostasis of CD4 CD25 regulatory T cells

31 March 2020

1 reference

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

31 March 2020

1 reference

Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors

31 March 2020

1 reference

High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma

31 March 2020

1 reference

Immune and clinical responses in patients with metastatic melanoma to CD34( ) progenitor-derived dendritic cell vaccine

31 March 2020

1 reference

12 December 2020

A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors

1 reference

12 December 2020

Functional aspects of the selective depletion of lymphoid tissue by cyclophosphamide.

1 reference

12 December 2020

Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases

1 reference

12 December 2020

Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators

1 reference

12 December 2020

Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors

1 reference

12 December 2020

50

61

6451

J Banchereau

2001

1 reference

8 December 2024

63

63

4490

AK Nowak

2003

1 reference

8 December 2024

Identifiers

DOI

10.1038/NRD3500

1 reference

Dimensions Publication ID

25 August 2017

1016806807

0 references

1 reference